Get startedLog in
    Picture of Zealand Pharma A/S logo

    ZEAL — Zealand Pharma A/S News Story

    0.000.00%
    dk flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMid CapNeutral
    All News

    Brief: Zealand Pharma Announces Positive Results From 28-Week Phase 1B Dapiglutide Trial

    Picture of Zealand Pharma A/S logoZealand Pharma A/S
    18/06/2025 16:36
    June 18 (Reuters) - Zealand Pharma A/S ZELA.CO:

ZEALAND PHARMA ANNOUNCES POSITIVE TOPLINE RESULTS FROM 28-WEEK PHASE 1B TRIAL WITH GLP-1/GLP-2 RECEPTOR DUAL AGONIST DAPIGLUTIDE

ZEALAND PHARMA A/S - MEAN BODY WEIGHT REDUCTION OF 11.6% AFTER 28 WEEKS WITH DAPIGLUTIDE

ZEALAND PHARMA A/S - DAPIGLUTIDE TREATMENT ASSESSED TO BE SAFE AND WELL-TOLERATED

ZEALAND PHARMA A/S - HIGHER DOSES OF DAPIGLUTIDE ASSESSED TO BE SAFE AND WELL-TOLERATED

Source text: ID:nGNX72XvDt

Further company coverage: ZELA.CO

    Recent news on Zealand Pharma A/S

    See all news